<DOC>
	<DOCNO>NCT01704261</DOCNO>
	<brief_summary>This study examine safety efficacy addition omarigliptin participant type 2 diabetes mellitus inadequate glycemic control metformin glimepiride . The primary hypothesis 24 week , addition treatment omarigliptin provide great reduction hemoglobin A1c ( A1C ) compare addition placebo .</brief_summary>
	<brief_title>Addition Omarigliptin ( MK-3102 ) Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Combination Therapy With Glimepiride Metformin ( MK-3102-022 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus Currently take stable dos metformin ( &gt; =1500 mg/day ) sulfonylurea Male , female reproductive potential female reproductive potential agrees remain abstinent use ( partner use ) 2 method acceptable contraception prevent pregnancy study 21 day last dose study drug History type 1 diabetes mellitus history ketoacidosis Treated antihyperglycemic agent therapy protocolrequired sulfonylurea metformin within 12 week prior study participation omarigliptin time prior study participation . History hypersensitivity dipeptidyl peptidase IV ( DPP4 ) inhibitor On weight loss program maintenance phase ; weight loss medication past 6 month ; undergone bariatric surgery within 12 month prior study participation . Is likely require treatment &gt; =2 consecutive week repeat course corticosteroid ( inhale , nasal topical corticosteroid permit ) Currently treat hyperthyroidism thyroid replacement therapy stable dose least 6 week Medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus ( HIV ) New worsen coronary heart disease , congestive heart failure , myocardial infarction , unstable angina , coronary artery intervention , stroke , transient ischemic neurological disorder within past 3 month Poorly control hypertension History malignancy &lt; =5 year prior study participation , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Pregnant breast feeding , expect conceive donate egg trial , include 21 day follow last dose study drug Current user recreational illicit drug recent history drug abuse routinely consume &gt; 2 alcoholic drink per day &gt; 14 drink per week , engage binge drinking Donated blood product within 8 week study participation , intend donate blood product study receive anticipates receive blood product within 12 week prior study participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>